GSK plc

6-K TOTAL VOTING RIGHTS Aug 3, 2026 6-K DIRECTOR/PDMR SHAREHOLDING Jul 30, 2026 6-K NEW GSK FLAGSHIP R&D CENTRE IN CAMBRIDGE Jul 28, 2026 6-K HANSOH POSITIVE 2ND PHASE III RESULTS FOR RIZ-REZ Jul 28, 2026 6-K 2ND QUARTER RESULTS Jul 28, 2026 6-K DIRECTOR/PDMR SHAREHOLDING Jul 24, 2026 6-K ADMISSION TO TRADING Jul 24, 2026 6-K JIDEYTRO APPROVED IN US FOR CERTAIN LUNG CANCERS Jul 22, 2026 6-K BEXSERO 1-DOSE BOOSTER EMA FILE ACCEPTANCE Jul 20, 2026 6-K AUDIT TENDER CONCLUSION Jul 17, 2026 6-K CAMLIPIXANT PHASE III RESULTS UPDATE Jul 17, 2026 6-K DIRECTOR/PDMR SHAREHOLDING Jul 16, 2026 6-K GSK COMPLETES ACQUISITION OF NUVALENT, INC Jul 15, 2026 6-K DIRECTOR/PDMR SHAREHOLDING Jul 14, 2026 6-K DIRECTOR/PDMR SHAREHOLDING Jul 13, 2026 6-K POSITIVE JEMPERLI DATA IN DMMR/MSI-H RECTAL CANCER Jul 13, 2026 6-K HANSOH POSITIVE PHASE III RESULTS FOR RIZ-REZ Jul 10, 2026 6-K DIRECTOR/PDMR SHAREHOLDING Jul 9, 2026 6-K DIRECTORATE CHANGE Jul 9, 2026 6-K TOTAL VOTING RIGHTS Jul 1, 2026 6-K TRANSACTION IN OWN SHARES Jun 29, 2026 6-K HOLDING(S) IN COMPANY Jun 29, 2026 6-K HOLDING(S) IN COMPANY Jun 26, 2026 6-K DIRECTOR/PDMR SHAREHOLDING Jun 24, 2026 6-K GSK ANNOUNCES TENDER OFFER TO ACQUIRE NUVALENT Jun 24, 2026 6-K DIRECTOR/PDMR SHAREHOLDING Jun 23, 2026 6-K TRANSACTION IN OWN SHARES Jun 22, 2026 6-K CUTI ORAL ANTIBIOTIC TEBIPENEM APPROVED BY US FDA Jun 17, 2026 6-K TRANSACTION IN OWN SHARES Jun 15, 2026 6-K MOMELOTINIB ORPHAN DRUG DESIGNATIONS FOR VEXAS Jun 12, 2026 6-K DIRECTOR/PDMR SHAREHOLDING Jun 11, 2026 6-K DIRECTOR/PDMR SHAREHOLDING Jun 10, 2026 6-K DR HAL BARRON - NEW DIRECTORSHIP Jun 9, 2026 6-K GSK ENTERS AGREEMENT TO ACQUIRE NUVALENT, INC. Jun 9, 2026 6-K TRANSACTION IN OWN SHARES Jun 8, 2026 6-K TOTAL VOTING RIGHTS Jun 1, 2026 6-K TRANSACTION IN OWN SHARES Jun 1, 2026 6-K POSITIVE PHASE 3 DATA FOR BEPIROVIRSEN May 28, 2026 6-K DIRECTOR/PDMR SHAREHOLDING May 27, 2026 6-K ADMISSION TO TRADING May 26, 2026